Epilepsy, a global neurological disorder affecting 1% of the population, results in recurrent seizures, significantly
impacting quality of life. This study assesses the cost-effectiveness of antiepileptic drugs (AEDs) for Generalised
Tonic-Clonic Seizure (GTCS) to enhance seizure control and overall patient outcomes. Conducted over six months
from April to September 2023 in the General Medicine Department, the study included 117 patients aged 10-80 years
diagnosed with GTCS. Exclusion criteria encompassed children under 10, pregnant or lactating women, patients on
multiple AEDs, those with AED resistance, and those unwilling to participate. Data collection encompassed
demographic, clinical, diagnostic, and prescription details, alongside cost and clinical outcomes. Statistical analysis
was focused on calculating Incremental Cost-Effectiveness Ratios (ICER). The results indicated that Tablet Sodium
Valproate, the most frequently prescribed drug, was administered at doses below WHO's ATC-defined daily doses and
emerged as the most cost-effective treatment for GTCS. In conclusion, this study identifies cost-effective antiepileptic
drug choices for generalised tonic-clonic seizures, providing valuable insights for patients, doctors and policy makers
to make judicious, economically sound treatment decisions, thereby improving epilepsy management.